Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;6(1):27-31.
doi: 10.21037/tp.2016.04.03.

Developmental delay and behavioral disorders in 59 HIV-exposed uninfected infants

Véronique Reliquet  1 , Cécile Brunet-Cartier  1 , Elise Launay  2 , François Raffi  1
Affiliations

Developmental delay and behavioral disorders in 59 HIV-exposed uninfected infants

Véronique Reliquet et al. Transl Pediatr. 2017 Jan.

Abstract

Background: Antiretroviral therapy (ART) in HIV pregnant women has led to a dramatic decrease in the rate of HIV mother-to-child transmission but this benefit is counterbalanced with adverse effects related to in utero and neonatal exposure to ART. In 2013, some parents described neurodevelopmental disorders in their children.

Methods: A standardized letter was sent to the 133 women who delivered in Nantes hospital from 01/01/2003 to 31/12/2012 (167 births).

Results: Response rate was 33%. Over a 10-year period, 7 children had behavioral disorders and/or cognitive/developmental delay, 1 child had developmental delay + growth retardation and 2 experienced cancer.

Conclusions: We found a significant association between neurodevelopmental disorders, preterm birth and exposure to 3 nucleoside reverse transcriptase inhibitors (NRTIs). Further studies are needed and long-term follow-up into adulthood should continue.

Keywords: Behavioral disorders; HIV-exposed uninfected infants (HEU); developmental delay.

PubMed Disclaimer

Conflict of interest statement

V Reliquet has received travel grants from Merck-Sharp and Dohme and honoraria from Gilead Sciences and Janssen-Cilag. F Raffi received research funding or honoraria from or consulted for Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Ferrer, Gilead Sciences, GlaxoSmith Kline, Janssen-Cilag, Merck-Sharp and Dohme, Pfizer, Splicos, ViiV Healthcare. C Brunet-Cartier received honoraria from Janssen-Cilag. E Launay has no conflicts of interest to declare.

References

    1. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Accessed 17 February, 2015. Available online: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf
    1. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003;17:1769-85. 10.1097/00002030-200308150-00006 - DOI - PubMed
    1. Noguera A, Fortuny C, Muñoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004;114:e598-603. 10.1542/peds.2004-0955 - DOI - PubMed
    1. Mofenson LM, Watts DH. Safety of pediatric HIV elimination: the growing population of HIV- and antiretroviral-exposed but uninfected infants. PLoS Med 2014;11:e1001636. 10.1371/journal.pmed.1001636 - DOI - PMC - PubMed
    1. Sirois PA, Huo Y, Williams PL, et al. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants. Pediatr Infect Dis J 2013;32:648-55. 10.1097/INF.0b013e318284129a - DOI - PMC - PubMed

LinkOut - more resources